Luk K H, Francis M E, Perez C A, Johnson R J
Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):801-9. doi: 10.1016/0360-3016(84)90380-8.
A registry established by the Radiation Therapy Oncology Group provides data for assessing the impact of clinical heating in a set of non-randomized patients treated with hyperthermia in participating member institutions from 1/77 to 6/81. This analysis focuses on tumor response when localized hyperthermia is produced by microwave and applied pursuant to two distinctly different treatment schedules. Hyperthermia treatments were biweekly and combined with daily radiation treatments in one patient group, and combined with biweekly radiation treatment in another. Sample X consists of 65 patients who received a course of therapy using combined hyperthermia and radiation in consecutive treatment sessions each separated by at least 48 hours, but no more than 96 hours. Sample Y consists of 34 patients who received further radiation after the start of a course of combined therapy--either between or at the end of a series of combined treatment sessions. The average length of heat treatment was 72 minutes for Sample X and 32 minutes for Sample Y patients. None of the patients received concurrent chemotherapy; all received between 3 and 13 hyperthermia treatments; all had superficial, measurable tumors. On the average, Sample X patients received 704 total minutes of heat compared to Sample Y patients who received 233 total minutes of heat. Total tumor radiation doses ranged from 17.0 Gy to 44.0 Gy among Sample X patients with 92.3% receiving radiation at either 3 Gy or 4 Gy per fraction. In Sample Y the range for total tumor dose was 16.0 Gy to 70.2 Gy with 73.4% of the patients receiving radiation at 2.5 Gy or less per fraction. Generally, the two treatment schedules achieved similar levels of tumor response. Among treated tumors in Sample X and Sample Y, complete regression rates were 52.4 and 61.8%, respectively, and partial regression rates were 16.9 and 14.7%. Adenocarcinoma and squamous cell carcinoma in both samples responded well to these combined treatments. Only in Sample X was there a statistically significant trend of decreasing complete regression rate when the treated tumor sizes increased. Best responses to treatment generally occurred between 28 and 84 days after completion of the combined therapy course. There were no differences between the two samples with respect to median days to best response or response duration. Blister, ulcer or wet desquamation were reported in 47.7% of Sample X as the maximum skin reaction. In contrast, only 20.6% of Sample Y had these complications.(ABSTRACT TRUNCATED AT 400 WORDS)
放射治疗肿瘤学组建立的一个登记处提供了数据，用于评估在1977年1月至1981年6月期间，参与成员机构中接受热疗的一组非随机患者中临床加热的影响。该分析聚焦于当通过微波产生局部热疗并按照两种截然不同的治疗方案应用时的肿瘤反应。热疗每两周进行一次，在一个患者组中与每日放疗相结合，在另一个患者组中与每两周一次的放疗相结合。样本X由65名患者组成，他们在连续的治疗疗程中接受了热疗与放疗联合治疗，每个疗程间隔至少48小时，但不超过96小时。样本Y由34名患者组成，他们在联合治疗疗程开始后接受了进一步放疗——在一系列联合治疗疗程之间或结束时。样本X患者的平均热疗时长为72分钟，样本Y患者为32分钟。所有患者均未接受同步化疗；所有患者均接受了3至13次热疗；所有患者均患有浅表、可测量的肿瘤。样本X患者平均接受了704分钟的热疗，而样本Y患者平均接受了233分钟的热疗。样本X患者的肿瘤总辐射剂量范围为17.0 Gy至44.0 Gy，92.3%的患者每次分割接受3 Gy或4 Gy的辐射。在样本Y中，肿瘤总剂量范围为16.0 Gy至70.2 Gy，73.4%的患者每次分割接受剂量为2.5 Gy或更低的辐射。一般来说，两种治疗方案达到了相似的肿瘤反应水平。在样本X和样本Y中接受治疗的肿瘤中，完全缓解率分别为52.4%和61.8%，部分缓解率分别为16.9%和14.7%。两个样本中的腺癌和鳞状细胞癌对这些联合治疗反应良好。仅在样本X中，当治疗的肿瘤大小增加时，完全缓解率有统计学意义的下降趋势。治疗的最佳反应通常发生在联合治疗疗程结束后的28至84天之间。在最佳反应的中位天数或反应持续时间方面，两个样本之间没有差异。样本X中有47.7%的患者报告出现水泡、溃疡或湿性脱皮作为最大皮肤反应。相比之下，样本Y中只有20.6%的患者有这些并发症。（摘要截选至400字）
